Core Insights - Dexcom presented breakthrough outcomes for Type 2 diabetes management and outlined its product roadmap at the ATTD 2026 conference, emphasizing the need for continuous glucose monitoring (CGM) to become standard care for all Type 2 diabetes patients, including those not on insulin therapy [1][2] Group 1: Product Features and Innovations - Dexcom showcased new registry study data indicating that long-term use of Dexcom G7 supports weight management and lowers A1C levels for non-insulin-treated Type 2 diabetes patients, highlighting the importance of CGM access for this demographic [1] - The company introduced its upcoming product features during the conference, including advancements in Dexcom G7 and Dexcom ONE+, as well as a new health and wellness product line called Stelo [1] - Dexcom's commitment to innovation includes the introduction of the Dexcom Academy, an education platform for healthcare professionals, which is currently available in several countries with plans for further expansion [1][2] Group 2: Clinical Evidence and Impact - A multi-center primary care registry study revealed that after one year of using Dexcom G7, non-insulin-treated Type 2 diabetes patients experienced significant improvements in A1C and weight management, reinforcing the benefits of CGM [1] - New evidence presented at the conference indicated that Dexcom CGM use is associated with reductions in diabetic ketoacidosis (DKA)-related hospitalizations and emergency room visits for both children and adults with Type 1 diabetes [1] - A prospective study demonstrated that Dexcom Smart Basal was safe and effective for optimizing basal insulin therapy in Type 2 diabetes patients, showcasing the technology's versatility [1] Group 3: Educational Initiatives - Dexcom introduced the first consensus-based CGM competency framework aimed at providing healthcare professionals with a structured approach to delivering CGM support, which will be utilized in the Dexcom Academy [1] - The company hosted symposiums at the conference to discuss the clinical implications of its technology and the benefits of early CGM use in prediabetes and Type 2 diabetes management [1]

Summary of the Conference Call Transcript Industry Overview - **Industry**: Pharmaceuticals - **Context**: The pharmaceutical sector is being upgraded to overweight as a diversifier amid geopolitical tensions, particularly in the Middle East. Traditional hedges like bonds have failed to provide diversification, leading investors to seek alternatives such as gold, defense stocks, and now pharmaceuticals [2][14]. Core Points and Arguments 1. **Performance of Pharmaceuticals**: - The global pharma sector has performed in line with the market since February 27, 2026, but historically, it has outperformed during oil supply-side shocks, with an average outperformance of 8% in the following three months [3][19]. - The sector is currently discounting a PMI of 52, indicating it is positioned defensively against economic downturns [4][34]. 2. **Economic Indicators**: - A 10% rise in oil prices is estimated to reduce global GDP by 0.2%, while a similar rise in European retail gas prices could reduce GDP by 0.1% [4][39]. - The IMF and UBS forecasts suggest that if GDP growth falls below 1.5%, pharmaceuticals are likely to outperform [4][38]. 3. **Financial Health**: - The pharmaceutical sector has low leverage, making it resilient during periods of rising credit spreads. High yield spreads are expected to rise from 2.9% to 3.25% [5][44]. - The sector is currently undervalued, trading at a P/E ratio on par with the market, which is below its historical norm of a 13% premium [6][60]. 4. **Technological Advancements**: - The integration of Gen AI and quantum computing is expected to enhance R&D productivity and accelerate drug discovery, particularly for chronic diseases [6][50][51]. - Gen AI could potentially halve the cost and time required to bring a drug to market, improving the overall efficiency of pharmaceutical companies [51]. 5. **Market Positioning**: - Pharmaceuticals are currently under-owned, ranking as the seventh most shorted sector globally [6][55]. - The top recommended stocks include Roche, AstraZeneca, Eli Lilly, and Merck, which are considered undervalued with positive earnings revisions [6][62]. Additional Important Insights - **Healthcare Equipment**: The healthcare equipment sector is also recommended for overweight positioning, scoring high on the global scorecard [7][63]. - **Funding Strategy**: To fund the overweight in pharmaceuticals, a reduction in bank holdings is suggested, particularly in the US, due to concerns over credit spreads and macroeconomic indicators [8][76]. - **Consumer Plays**: In a scenario where the Middle East conflict resolves quickly, there is a favorable outlook for European consumer plays, with a small overweight in European banks maintained [9][76]. Conclusion The pharmaceutical sector is positioned as a strong defensive play amid current geopolitical tensions and economic uncertainties. With low leverage, potential for technological advancements, and favorable market conditions, it presents a compelling investment opportunity.

Company Overview - DexCom, Inc. is a medical device company based in San Diego, California, specializing in continuous glucose monitoring (CGM) systems for diabetes and metabolic health management [1] - The company has a market capitalization of $28.1 billion, positioning it as a large-cap stock within the medical devices industry [2] Stock Performance - DXCM stock reached a 52-week high of $89.98 on July 30, 2025, but has since declined by 19% from that peak [3] - Over the past three months, the stock has gained 11.7%, outperforming the Nasdaq Composite, which has slipped by 3% during the same period [3] - In the longer term, DXCM has declined by 11.6% over the past 52 weeks, underperforming the Nasdaq Composite's return of 24.7% [3] Trading Indicators - The stock has been trading below its 200-day moving average since last year, with fluctuations, but has remained above its 50-day moving average since mid-February [4] Financial Performance - Following the release of better-than-expected Q4 2025 earnings, DXCM stock surged by 7.6% [5] - The company's revenue grew nearly 13% year-over-year to $1.3 billion, surpassing Wall Street estimates [5] - Adjusted EPS for the quarter was $0.68, also exceeding expectations, and the company anticipates revenue for the next fiscal year to be between $5.2 billion and $5.3 billion, indicating an annual growth of 11% to 13% [5] Analyst Sentiment - Compared to its closest peer, STERIS plc, which has increased by 7.6% over the past year, DXCM has underperformed [6] - Wall Street analysts maintain a favorable view of DXCM, with a consensus rating of "Strong Buy" among 28 analysts and a mean price target of $85.36, suggesting a 17.1% upside potential from current levels [6]

Core Insights - Dexcom Inc. (DXCM) has received positive market interest recently, indicating a favorable perception of the company's performance and prospects in the biosensing technology sector [1] Company Overview - Dexcom Inc. is recognized as a pioneering firm in the medical equipment industry, specifically in the field of biosensing technology [1]

Core Insights - Dexcom Inc. (DXCM) has received positive market interest recently, indicating a favorable outlook for the company in the biosensing technology sector [1] Company Overview - Dexcom Inc. is recognized as a pioneering firm in the field of biosensing technology, which positions it as a significant player in the medical equipment industry [1]

Core Insights - DexCom is a leader in the biosensing industry, specifically known for its continuous glucose monitoring systems [3]. Company Overview - DexCom has a history of innovation, being the first to implement various features such as alerts and the iCGM standards [3]. - The company has consistently participated in significant industry conferences, highlighting its commitment to engaging with investors and stakeholders [1].

Summary of Dexcom's Conference Call Company Overview - **Company**: Dexcom - **Industry**: Continuous Glucose Monitoring (CGM) - **Key Personnel**: CFO Jereme Gloekler, new CEO Jake Leach, former Executive Chairman Kevin Sayer [1][2][6] Core Points and Arguments - **Market Size and Growth**: - Approximately 600 million people globally diagnosed with diabetes, expected to rise to 853 million by 2050 [5] - 40% of the U.S. population has prediabetes, indicating a growing crisis [5] - Only 2% of the diabetes population currently uses CGM, highlighting a significant unmet need [6] - **Company Strategy**: - Focus on being the premier glucose sensing solution and improving customer experience [7][9] - Plans to expand internationally, as Dexcom is under-indexed outside the U.S. [10] - Aiming for scalable production, with a goal to produce as many sensors as Apple makes iPhones [10] - **Financial Performance**: - Revenue growth of approximately 15% organically in 2025, with an active customer base growth of over 20% [12] - Guidance for 2026 includes revenue growth of 11%-13%, gross margins of 63%-64%, and over $1 billion in free cash flow [15][40] - **Product Developments**: - Launch of Dexcom G7 15-Day system, which includes SmartBasal for remote insulin titration [13][14] - Introduction of Dexcom ONE, an over-the-counter product, generating $130 million in revenue in 2025 [31] - Upcoming Dexcom G8 expected to be the most accurate sensor with advanced sensing capabilities [35][36] - **Clinical Evidence and Coverage**: - Ongoing efforts to secure coverage for Type 2 diabetes patients, with potential to unlock 12 million additional lives [21] - Real-world data shows significant health improvements for users of CGM, including reductions in A1C, weight, and BMI [19][20] Additional Important Content - **Customer Experience Enhancements**: - Development of a digital experience for better customer support and account management [27] - Integration with electronic health records (EHR) to facilitate data sharing with healthcare providers [30] - **International Expansion**: - Significant opportunities in countries like Japan, France, and Canada, where coverage is expanding [22][23] - Plans to launch a manufacturing facility in Ireland by 2026 to enhance global supply chain resilience [34][35] - **Challenges and Learnings**: - Acknowledgment of past challenges, including supply chain issues and an FDA warning letter, with a focus on learning and improving operations [44][45] - **Future Outlook**: - Anticipation of double-digit growth and gross margin expansion, with a strong emphasis on expanding coverage and improving product offerings [40][46] This summary encapsulates the key points discussed during the conference call, highlighting Dexcom's strategic direction, market opportunities, and financial outlook.

Core Insights - DexCom, Inc. has appointed Rick Osterloh to its Board of Directors, effective February 26, 2026, enhancing its leadership team with a seasoned technology executive [1][2]. Company Overview - DexCom is a leader in glucose biosensing technology, having pioneered advancements in this field for over 25 years, significantly transforming diabetes management and glucose tracking for users [6]. Leadership Appointment - Rick Osterloh brings over 20 years of experience in consumer hardware and product operations, currently serving as Senior Vice President at Google, where he oversees a unified group that includes Android, Google Play, Chrome, and various consumer devices [2][4]. - Osterloh's expertise includes innovation oversight, strategic transactions, and long-term planning, which aligns with DexCom's vision for product development [2][3]. Strategic Vision - The appointment of Osterloh is seen as a strategic move to leverage his insights into creating impactful products that integrate innovative technologies, which is crucial for advancing DexCom's mission to improve metabolic health globally [3][4].

Group 1: Market Overview - U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index increasing by 1.10% [1] - Within the Russell 1000 Growth Index, healthcare, communication services, and financials were the top-performing sectors, while utilities, real estate, and materials lagged [1] - The U.S. economy showed resilience, but consumer confidence deteriorated toward year-end, raising concerns about future spending and the labor market [1] Group 2: Fund Performance - The Aristotle Growth Equity Fund (Class I-2) returned 0.95%, underperforming the Russell 1000 Growth Index's 1.12% [1] - Poor security selection in the information technology and consumer discretionary sectors detracted from performance, while positive contributions from healthcare and industrials improved relative performance [1] Group 3: Company Focus - DexCom, Inc. - DexCom, Inc. (NASDAQ:DXCM) is a leading medical device company specializing in continuous glucose monitoring (CGM) systems for diabetes management [2][3] - As of February 25, 2026, DexCom, Inc. stock closed at $73.16 per share, with a one-month return of -1.14% and a 52-week loss of 16.68% [2] - DexCom has a market capitalization of $28.534 billion [2] - Key products include the Dexcom G7 CGM system and Stelo Glucose Biosensor, serving users with Type 1 or Type 2 diabetes and marketed primarily to healthcare professionals [3]

Core Insights - The GLP-1 drug market is rapidly growing, providing significant financial opportunities for pharmaceutical companies and their shareholders [1] - DexCom, a leader in continuous glucose monitoring (CGM) systems, is positioned to benefit from the GLP-1 boom without competing directly with drugmakers [2][4] Company Overview - DexCom specializes in developing and marketing CGM systems that track blood glucose levels in real-time, establishing itself as a leader in this niche [4] - The rise of GLP-1 drugs has not negatively impacted DexCom; rather, studies indicate that using CGM devices alongside GLP-1 medications leads to improved patient outcomes [4][5] Market Dynamics - Adoption of CGM devices has accelerated among GLP-1 users, as physicians increasingly prescribe both treatments together, enhancing patient health management [5] - The demand for DexCom's devices is expected to grow as GLP-1 prescriptions increase, regardless of which pharmaceutical company leads the market [6] Growth Potential - DexCom's addressable market remains underpenetrated, with over 9 million patients in the U.S. eligible for CGM reimbursement but not yet utilizing the devices; the current global installed base is approximately 2.5 million patients [7] - Continuous innovations, market expansion, and efforts to secure broader reimbursement are key factors driving DexCom's financial success, making its stock an attractive investment opportunity [8]